Below is a list of commonly asked question regarding Hepatitis C
1. What is hepatitis C?
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV), which is found in the blood of persons who have this disease. HCV is spread by contact with the blood of an infected person. Once exposed, 85% of these individuals become chronically infected, with a 15% chance of developing cirrhosis, which is scarring of the liver, over a 25 year time frame.
2. What blood tests are available to check for hepatitis C?
There are several blood tests that can be done to determine if you have been infected with HCV. You may need to be tested with one or two of the tests listed below to confirm the diagnosis:
a) Anti-HCV (antibody to HCV)
RIBA (recombinant immunoblot assay) A supplemental test used to confirm a positive EIA test Anti-HCV does not tell whether the infection is new (acute), chronic (long-term) or is no longer present. In most cases, this test is no longer used.
b) Qualitative tests to detect presence or absence of virus (HCV RNA)
This test will be reported as either positive (virus present) or negative (no virus present)
c) Quantitative tests to detect amount (titer) of virus (HCV RNA)
A single positive PCR test indicates infection with HCV. A single negative test does not prove that a person is not infected. Virus may be present in the blood and just not found by PCR. Also, a person infected in the past who has recovered may have a negative test.
When hepatitis C is suspected and PCR is negative, PCR should be repeated. This test will be reported as a “viral load”, determining the amount of virus present. This viral load becomes most important during treatment to determine if the is a response to therapy.
3. Can you have a "false positive" anti-HCV test result?
Yes. A false positive test means the test looks as if it is positive, but it is really negative. This happens more often in persons who have a low risk for the disease for which they are being tested. For example, false positive anti-HCV tests happen more often in persons such as blood donors who are at low risk for hepatitis C. Therefore, it is important to confirm a positive anti-HCV test with a supplemental test as most false positive anti- HCV tests are reported as negative on supplemental testing
4. Can you have a "false negative" anti-HCV test result?
Yes. Persons with early infection may not as yet have developed antibody levels high enough that the test can measure. In addition, some persons may lack the (immune) response necessary for the test to work well.
5. How long after exposure to HCV does it take to test positive for anti-HCV?
Anti-HCV can be found in 7 out of 10 persons when symptoms begin and in about 9 out of 10 persons within 3 months after symptoms begin. However, it is important to note that many persons who have hepatitis C have no symptoms.
6. How long after exposure to HCV does it take to test positive with PCR?
It is possible to find HCV within 1 to 2 weeks after being infected with the virus.
7. Who should get tested or hepatitis C?
8.Can you have a normal liver enzyme (e.g., ALT) level and still have chronic hepatitis C?
Yes. It is common for persons with chronic hepatitis C to have a liver enzyme level that goes up and down, with periodic returns to normal or near normal. Some persons have a liver enzyme level that is normal for over a year but they still have chronic liver disease. If the liver enzyme level is normal, persons should have their enzyme level re-checked several times over a 6 to 12 month period.
9. How could a person have been exposed to hepatitis C?
HCV is spread primarily by direct contact with human blood. For example, you may have gotten infected with HCV if:
10. Can HCV be spread by sexual activity?
Yes, but this does not occur very often. Discuss these issues with Dr. Galati for further information and guidance.
11. Can HCV be spread by oral sex?
There is no evidence that HCV has been spread by oral sex. Discuss these issues with Dr. Galati for further information.
12. Can HCV be spread within a household?
Yes, but this does not occur very often. If HCV is spread within a household, it is most likely due to direct exposure to the blood of an infected household member. Casual hosehold contact is not a risk factor for hepatitis C.
13. Since more advanced tests have been developed for use in blood banks, what is the chance now that a person can get HCV infection from transfused blood or blood products?
Less than 1 chance per million units transfused.
14. Should pregnant women be routinely tested for anti-HCV?
No. Pregnant women have no greater risk of being infected with HCV then non-pregnant women. If a pregnant woman has risk factors for hepatitis C, they should be tested for anti-HCV.
15. What is the risk that HCV infected women will spread HCV to their newborn infants?
About 5 out of every 100 infants born to HCV infected women become infected. This occurs at the time of birth, and there is no treatment that can prevent this from happening. Most infants infected with HCV at the time of birth have no symptoms and do well during childhood. More studies are needed to find out if these children will have problems from the infection as they grow older. There are no treatments or guidelines for the treatment of infants or children infected with HCV. Children with elevated ALT (liver enzyme) levels should be referred for evaluation to a specialist familiar with the management of children with HCV-related disease.
16. Should a woman with hepatitis C be advised against breast-feeding?
No. There is no evidence that breast-feeding spreads HCV. HCV-positive mothers should consider abstaining from breast-feeding if their nipples are cracked or bleeding.
17. When should babies born to mothers with hepatitis C be tested to see if they were infected at birth?
Children should not be tested for anti-HCV before 12-18 months of age as HCV antibodies from the mother may last until this age. If testing is desired prior to 12 months of age, PCR could be performed at or after an infant's first well-child visit at age 1-2 months.
18. How can persons infected with HCV prevent spreading HCV to others?
Do not donate blood, body organs, other tissue, or semen.
Do not share personal items that might have your blood on them, such as toothbrushes, dental appliances, nail-grooming equipment or razors.
Cover your cuts and skin sores to keep from spreading HCV.
19. How can a person protect themselves from getting hepatitis C and other diseases spread by contact with human blood?
Don't ever shoot drugs. If you shoot drugs, stop and get into a treatment program. If you can't stop, never reuse or share syringes, water, or drug works, and get vaccinated against hepatitis A and hepatitis B.
HCV can be spread by sex, but this does not occur very often. If you are having sex, but not with one steady partner:
You and your partners can get other diseases spread by having sex (e.g., AIDS, hepatitis B, gonorrhea or chlamydia).
19. Should patients with hepatitis C change their sexual practices if they have only one long-term steady sex partner?
No. There is a very low chance of spreading HCV to that partner through sexual activity. If you want to lower the small chance of spreading HCV to your sex partner, you may decide to use barrier precautions such as latex condoms. The efficacy of latex condoms in preventing infection with HCV is unknown, but their proper use may reduce transmission. Your partner should also be tested.
20. What can persons with HCV infection do to protect their liver?
Stop using alcohol.
See your doctor regularly.
Don't start any new medicines or use over-the-counter, herbal, and other medicines without a physician's knowledge.
Get vaccinated against hepatitis A and B
21. What other information should patients with hepatitis C be aware of?
Sneezing, hugging, coughing, food or water does not spread HCV nor does sharing eating utensils or drinking glasses, or casual contact.
Persons should not be excluded from work, school, play, child-care or other settings on the basis of their HCV infection status.
22. What are the chances of persons with HCV infection developing long term infection, chronic liver disease, cirrhosis, liver cancer, or dying as a result of hepatitis C?
Of every 100 persons infected with HCV about:
75 to 85 persons may develop long-term infection
70 persons may develop chronic liver disease
15 persons may develop cirrhosis over a period of 20 to 30 years
Less than 3% of persons may die from the consequences of long term infection (liver cancer or cirrhosis)
Hepatitis C is a leading indication for liver transplants.
23. Do medical conditions outside the liver occur in persons with chronic hepatitis C?
A small percentage of persons with chronic hepatitis C develop medical conditions outside the liver (this is called extrahepatic). These conditions are thought to occur due to the body's natural immune system fighting against itself. Such conditions include: glomerulonephritis associated with kidney disease, essential mixed cryoglobulinemia, and porphyria cutanea tarda-a skin condition.
24. What is the treatment for chronic hepatitis C?
Combination therapy with pegylated interferon and ribavirin is the treatment of choice resulting in sustained response rates (clearing the virus) of 40%-80%. (up to 50% for patients infected with the most common genotype found in the U.S. [genotype 1] and up to 80% for patients infected with genotypes 2 or 3). Interferon monotherapy used on its own is generally reserved for patients in whom ribavirin is not indicated. Ribavirin, when used alone, does not work.
25. What are the side effects of interferon therapy?
Most persons have flu-like symptoms (fever, chills, headache, muscle and joint aches, fast heart rate) early in treatment, but these lessen with continued treatment. Later side effects may include tiredness, mild hair loss, low blood count, trouble with thinking, moodiness, and depression. Severe side effects are rare (seen in less than 2 out of 100 persons). These include thyroid disease, depression with suicidal thoughts, seizures, acute heart or kidney failure, eye and lung problems, hearing loss, and blood infection.
Although rare, deaths have occurred due to liver failure or blood infection, mostly in persons with cirrhosis. An important side effect of interferon is worsening of liver disease with treatment, which can be severe and even fatal. This is usually seen in patients that have cirrhosis and advanced liver disease. Interferon dosage must be reduced in up to 40 out of 100 persons because of severity of side effects, and treatment must be stopped in up to 15 out of 100 persons. Pregnant women should not be treated with interferon.
26. What are the side effects of combination (ribavirin + interferon) treatment?
In addition to the side effects due to interferon described above, ribavirin can cause serious anemia (low red blood cell count) and can be a serious problem for persons with conditions that cause anemia, such as kidney failure. In these persons, combination therapy should be avoided or attempts should be made to correct the anemia. Anemia caused by ribavirin can be life-threatening for persons with certain types of heart or blood vessel disease. Ribavirin causes birth defects and pregnancy should be avoided during treatment. Patients should carefully review the product manufacturer information prior to treatment.
27. Can anything be done to reduce symptoms or side effects due to antiviral treatment?
You should report what you are feeling to Dr. Galati and the treatment team at every visit or as they develop. Giving interferon at night or lowering the dosage of the drug may reduce some side effects. In addition, taking acetaminophen or ibuprofen before treatment can reduce flu-like symptoms.
28. What does the term genotype mean?
Genotype refers to the genetic make-up of an organism or a virus. There are at least 6 distinct HCV genotypes identified. Genotype 1 is the most common genotype seen in the United States.
29. Is it necessary to do genotyping when managing a person with chronic hepatitis C?
Yes, as there are 6 known genotypes and more than 50 subtypes of HCV, and genotype information is helpful in defining the epidemiology of hepatitis C. Knowing the genotype or serotype (genotype-specific antibodies) of HCV is helpful in making recommendations and counseling regarding therapy. Patients with genotypes 2 and 3 are almost three times more likely than patients with genotype 1 to respond to therapy with alpha interferon or the combination of alpha interferon and ribavirin.
Furthermore, when using combination therapy, the recommended duration of treatment depends on the genotype. For patients with genotypes 2 and 3, a 24-week course of combination treatment is adequate, whereas for patients with genotype 1, a 48-week course is recommended. For these reasons, testing for HCV genotype is often clinically helpful. Once the genotype is identified, it need not be tested again; genotypes do not change during the course of infection.
30. What is the risk for HCV infection from a needle-stick exposure to HCV contaminated blood?
After needle stick or sharps exposure to HCV positive blood , about 2 healthcare workers out of 100 will get infected with HCV.
31. What are the recommendations for follow-up of healthcare workers after exposure to HCV positive blood?
Anti-viral agents (e.g., interferon) or immune globulin should not be used for postexposure prophylaxis.
For the source, baseline testing for anti-HCV.
For the person exposed to an HCV-positive source, baseline and follow-up testing including baseline testing for anti-HCV and ALT activity; and follow-up testing for anti-HCV (e.g., at 4-6 months) and ALT activity. (If earlier diagnosis of HCV infection is desired, testing for HCV RNA may be performed at 4-6 weeks.)
32. Should HCV-infected healthcare workers be restricted in their work?
No, there are no recommendations to restrict a healthcare worker who is infected with HCV. The risk of transmission from an infected healthcare worker to a patient appears to be very low. As recommended for all healthcare workers, those who are HCV positive should follow strict aseptic technique and standard precautions, including appropriate use of hand washing, protective barriers, and care in the use and disposal of needles and other sharp instruments.